Stay updated on Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial page
- Check5 days agoChange DetectedA centralized 'Locations' section was added, listing Massachusetts and New York sites, consolidating the previous state-specific location headings. The separate 'Massachusetts Locations' and 'New York Locations' subsections were removed, and the HHS Vulnerability Disclosure link was deleted.SummaryDifference0.3%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check33 days agoChange DetectedPublications are now described as automatically filled from PubMed and may not all pertain to the study, and the page revision has been updated to v3.3.2.SummaryDifference0.1%

- Check41 days agoChange DetectedThe banner about government funding status and operating status has been removed from the page.SummaryDifference0.4%

- Check55 days agoChange DetectedNo significant additions or deletions were detected; the Study Details page content appears unchanged, including eligibility criteria and locations.SummaryDifference0.4%

- Check84 days agoChange DetectedUpdate includes a prominent operating-status notice and a version upgrade from v3.1.0 to v3.2.0. The core effect is informing users about possible delays and the current open status of the NIH Clinical Center.SummaryDifference3%

- Check91 days agoChange Detected- Added a new version tag (v3.1.0). - Removed a specific resource (Ovarian cancer) and an older revision tag (v3.0.2).SummaryDifference0.3%

Stay in the know with updates to Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & PLD in Platinum Resistant Ovarian Cancer Clinical Trial page.